FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, particularly to an antibody or a fragment thereof, which specifically bind the human glucagon receptor (GCGR). Also disclosed is a polynucleotide coding said antibody; expression vector containing said polynucleotide; cell containing said vector; pharmaceutical composition containing said antibody. Disclosed is a method of producing said antibody.
EFFECT: invention makes it possible to effectively treat diseases, disorders and pathological conditions associated with high blood glucose levels.
38 cl, 7 ex, 14 tbl, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| C3 BINDING AGENTS AND METHODS OF THEIR USE | 2019 |
|
RU2802307C2 |
| ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN AND METHODS OF THE USE THEREOF | 2015 |
|
RU2766094C2 |
| MICA/B ANTIBODIES BLOCKING MICA/B SHEDDING AND METHODS OF USE THEREOF | 2019 |
|
RU2815101C2 |
| METHOD FOR PREPARING ANTIBODY-DRUG CONJUGATE BASED ON ERIBULIN | 2020 |
|
RU2840013C1 |
| PMEL17 ANTIBODIES AND CONJUGATES BASED THEREON | 2019 |
|
RU2831785C2 |
| ST2 ANTIGEN BINDING PROTEIN | 2021 |
|
RU2841164C2 |
| MONOCLONAL ANTIBODY TO NAV1.7 | 2019 |
|
RU2776821C2 |
| ANTIBODIES TO CHIMERIC ANTIGEN RECEPTORS DERIVED FROM 4G7 | 2020 |
|
RU2826051C2 |
| ANTIBODIES AGAINST IL-7R ALPHA SUBUNIT AND THEIR USE | 2020 |
|
RU2811912C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
